colchicine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	deaths E	clinical improvement E	death or ventilation E
COVID 19 hospitalized meta-analysis
COLCOVID NCT04328480		RCT	colchicine	standard of care	COVID 19 hospitalized	some concern	640/639	inconclusive
Gaitan-Duarte (Rosuvastatin plus colchicine) NCT04359095		RCT	Colchicine plus rosuvastatin	standard of care	COVID 19 hospitalized	some concern	161/162	inconclusive
Horby NCT04381936		RCT	colchicine	standard of care	COVID 19 hospitalized	some concern	5610/5730	inconclusive
RECOVERY (colchicine) NCT04381936		RCT	colchicine	standard of care	COVID 19 hospitalized	some concern	5610/5730	inconclusive
GRECCO-19 NCT04326790		RCT	colchicine	standard of care	COVID 19 hospitalized	some concern	55/50	suggested
Salehzadeh IRCT20200418047126N1		RCT	colchicine	placebo	COVID 19 hospitalized	some concern	50/50	inconclusive
COVID-19 mild to moderate meta-analysis
COL-COVID (Pascual-Figal) NCT04350320		RCT	colchicine	standard of care	COVID-19 mild to moderate	some concern	52/51	inconclusive
5 studies excluded by filtering options (2 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis